Research And Markets - Is Pharmacologic Treatment Of Psychiatric Indications Is Evolving?

(PRWEB) December 8, 2004 -- Because of the great cross-over of psych drug classes into many different clinical applications, the Report is broken out into two major sections - drug classes and clinical markets. The Report reviews drugs in the pipeline and provides a sophisticated analysis of changing clinical practices, market dynamics, and informed projections.

Research and Markets (http://www.researchandmarkets.com/reports/c10616) has announced the addition of Psychiatric Drugs: New Developments and Market Analysis by Drug Class and Clinical Indication to their offering

This Report provides a large database of important classes of psychiatric drugs in development and the multiple indications for which they will be used. In addition, the Report includes a sophisticated analysis of clinical trends (such as and combination drug therapy) and market dynamics.

Psychiatric disorders have an immense impact on the lives of more than 1/5 of population and the economies of the Western world. In the U.S., in any given year, it is estimated that 22.1% of adults ages 18 and older-about 45 million-suffer from a diagnosable psychiatric (or mental) disorder.

Furthermore, four of the 10 leading causes of disability in the U.S. and other developed countries are psychiatric disorders-major depression, bipolar disorder, schizophrenia, and obsessive-compulsive disorder.

Pharmacologic treatment of psychiatric indications is evolving, as the number of new compounds in development for these indications continues to grow, enabled by basic neuroscience research and pharmaceutical R&D efforts that are broad and deep.

During the last two decades many new drugs for psychiatric indications have been introduced, paradigm shifts in treatment of major disorders have occurred, and huge and expanding pharmaceutical markets have emerged.

For more information visit http://www.researchandmarkets.com/reports/c10616

Laura Wood

Senior Manager

Research and Markets

press@researchandmarkets.com

Fax: +353 1 4100 980

###